Soleno Therapeutics (SLNO) Net Income towards Common Stockholders: 2013-2024
Historic Net Income towards Common Stockholders for Soleno Therapeutics (SLNO) over the last 9 years, with Dec 2024 value amounting to -$175.8 million.
- Soleno Therapeutics' Net Income towards Common Stockholders rose 79.18% to -$544,000 in Q4 2017 from the same period last year, while for Dec 2017 it was -$3.6 million, marking a year-over-year increase of 75.21%. This contributed to the annual value of -$175.8 million for FY2024, which is 353.15% down from last year.
- Soleno Therapeutics' Net Income towards Common Stockholders amounted to -$175.8 million in FY2024, which was down 353.15% from -$38.8 million recorded in FY2023.
- Over the past 5 years, Soleno Therapeutics' Net Income towards Common Stockholders peaked at -$24.1 million during FY2022, and registered a low of -$175.8 million during FY2024.
- Its 3-year average for Net Income towards Common Stockholders is -$79.6 million, with a median of -$38.8 million in 2023.
- Data for Soleno Therapeutics' Net Income towards Common Stockholders shows a maximum YoY slumped of 353.15% (in 2024) over the last 5 years.
- Yearly analysis of 3 years shows Soleno Therapeutics' Net Income towards Common Stockholders stood at -$24.1 million in 2022, then tumbled by 61.04% to -$38.8 million in 2023, then crashed by 353.15% to -$175.8 million in 2024.